Dual-Action Therapy Extends Mouse Lifespan by Over 70 Percent

The research, involving a broad coalition of institutions including the Buck Institute and Stanford University, targets senescent cells—so-called zombie cells—that drive chronic inflammation and tissue dysfunction. The treatment sequence begins with SenoVax, an immune-based therapy designed to train the body to recognize and eliminate these resistant cells. Once the inflammatory drivers are removed, the protocol introduces StemCellRevivify, a platform utilizing mesenchymal stem cells to facilitate systemic repair.

Thomas Ichim, president of Immorta Bio, noted that the results exceeded internal expectations, validating a concept that has been under development for three years. Francesco M. Marincola, chief scientific officer at TAM Global, emphasized that clearing the pathological environment first creates a more permissive state for regeneration. This suggests that the tandem approach is more effective than individual interventions. Beyond raw lifespan extension, the study holds potential implications for treating cardiovascular, neurodegenerative, and metabolic disorders, which share aging as a common root mechanism. The team is now moving toward further mechanistic analysis to determine pathways for human clinical application.